Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels.
ABSTRACT We have previously shown that Docetaxel-induced variable degrees of apoptosis in melanoma. In this report, we studied the beta-tubulin repertoire of melanoma cell lines and show that class III beta-tubulin expression correlated with Docetaxel-resistance. Sensitive cells showed low levels of class III beta-tubulin with little microtubular incorporation, whereas class III beta-tubulin expression was higher in resistant cells and was incorporated into the cytoskeleton. As proof of concept, abrogation of class III by siRNA reverted Docetaxel-resistant cells to a sensitive phenotype, restoring the microtubular polymerisation response and promoting high levels of apoptosis through Bax activation. These results suggest that phenotypic expression of beta-tubulin class III in melanoma may help identify patients with melanoma that can respond to taxanes.
- SourceAvailable from: upmc.fr[show abstract] [hide abstract]
ABSTRACT: Over the past decade, significant progress has been made in our understanding of the biology of microtubule (MT) assembly into the mitotic spindle during mitosis and the molecular signaling and execution of the various pathways to apoptosis. In the same period, the microtubule-targeted tubulin-polymerizing agents (MTPAs), notably paclitaxel and taxotere, have come to occupy a central role in the treatment of a variety of human epithelial cancers. Following their binding to B-tubulin, MTPAs inhibit MT dynamic instability, cell cycle G2/M phase transition and mitotic arrest of cancer cells. MTPA-induced anti-MT and cell cycle effects trigger the molecular signaling for the mitochondrial pathway of apoptosis. This triggering is orchestrated through different molecular links and determined by the threshold for apoptosis that is set and controlled diversely in various cancer types. The complexity and regulatory potential of the links and the apoptosis threshold are integral to the transformed biology of the cancer cell. The emerging understanding of this biology and how it is influenced by treatment with MTPAs has highlighted novel strategies to further enhance the antitumor activity and overcome resistance to MTPA-induced apoptosis in cancer cells.Oncogene 01/2004; 22(56):9075-86. · 7.36 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: Taxol may contribute to intrinsic chemoresistance by activating the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) cytoprotective pathway in human cancer cell lines and tumors. We have previously shown additivity between Taxol and the MEK inhibitor, U0126 in human cancer cell lines. Here, the combination of Taxol with an orally bioavailable MEK inhibitor, CI-1040, was evaluated in human lung tumors heterotransplanted into nude mice. Unlike xenograft models that are derived from cells with multiple genetic alterations due to prolonged passage, heterotransplanted tumor models are more clinically relevant. Combined treatment with both drugs resulted in inhibition of tumor growth in all models and tumor regressions in three of four models tested, supporting our previous observation that Taxol's efficacy is potentiated by MEK inhibition. Concurrent administration was superior to intermittent dosing. Pharmacodynamic assessments of tumors indicated that suppression of MEK was associated with induction of S473 phosphorylated Akt and reduced proliferation in the combination groups relative to single agents, in addition to suppression of fibroblast growth factor-mediated angiogenesis and reduced expression of vascular endothelial growth factor. These findings are significant and indicate that this combination may have broad therapeutic applications in a diverse range of lung tumors with different intrinsic chemosensitivities.Cancer Research 05/2005; 65(7):2854-60. · 8.65 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: We have previously shown that Smac/DIABLO release from mitochondria appears to be the principal pathway by which TRAIL induces apoptosis of human melanoma. We report that TRAIL-induced release of Smac/DIABLO appears to be downregulated by concomitant signaling through the MEK Erk1/2 kinase pathway and that this inhibits TRAIL-induced apoptosis. Inhibition of Erk1/2 signaling by either the MEK inhibitor U0126 or a dominant-negative mutant of MKK1 markedly sensitized melanoma cells to TRAIL-induced apoptosis. The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126. Caspase-3 activation and cleavage of its substrates, PARP, ICAD and XIAP, were however increased by cotreatment with U0126. This was associated with a rapid reduction in mitochondrial transmembrane potential (MMP) and increased release of Smac/DIABLO into the cytosol. Exploration of events leading to the changes in MMP revealed an increased translocation of Bax from the cytosol to mitochondria in the presence of U0126. There was also a delayed decrease in the levels of expression of Mcl-1. Bcl-2 and Bcl-X(L). Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126. Cytochrome c appeared not to play a major role in sensitization of melanoma to TRAIL in that caspase-9 activation was not detected in most of the cell lines. These results suggest that Erk1/2 signaling may protect melanoma cells against TRAIL-induced apoptosis by inhibiting the relocation of Bax from the cytosol to mitochondria and that this may reduce TRAIL-mediated release of Smac/DIABLO and induction of apoptosis.Oncogene 06/2003; 22(19):2869-81. · 7.36 Impact Factor
Melanoma cell sensitivity to Docetaxel-induced apoptosis is
determined by class III b-tubulin levels
Nizar M. Mhaidata,1, Rick F. Thorneb,1, Charles Edo de Bockc, Xu Dong Zhangd, Peter Herseyd,*
aDepartment of Clinical Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan
bCancer Research Unit at the University of Newcastle, University Drive, Callaghan Newcastle, NSW 2308, Australia
cQueensland Institute of Medical Research, Herston, QLD 4006, Australia
dImmunology and Oncology Unit, Room 443, David Maddison Clinical Sciences Building, Cnr. King & Watt Streets, Newcastle, NSW 2300, Australia
Received 25 October 2007; accepted 6 December 2007
Available online 18 December 2007
Edited by Richard Marais
variable degrees of apoptosis in melanoma. In this report, we
studied the b-tubulin repertoire of melanoma cell lines and show
that class III b-tubulin expression correlated with Docetaxel-
resistance. Sensitive cells showed low levels of class III b-tubulin
with little microtubular incorporation, whereas class III b-tubu-
lin expression was higher in resistant cells and was incorporated
into the cytoskeleton. As proof of concept, abrogation of class
III by siRNA reverted Docetaxel-resistant cells to a sensitive
phenotype, restoring the microtubular polymerisation response
and promoting high levels of apoptosis through Bax activation.
These results suggest that phenotypic expression of b-tubulin
class III in melanoma may help identify patients with melanoma
that can respond to taxanes.
? ? 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
We have previously shown that Docetaxel-induced
Keywords: Melanoma; Docetaxel; Class III b-tubulin;
Given the pivotal importance of microtubules in many cellu-
lar functions, they have been the targets for anticancer drugs
such as taxanes and vinca alkaloids. By interfering with the
agents exert profound effects on cellular processes such as gene
expression, cell cycle arrest, and apoptosis [1,2]. Taxanes rep-
resent an important class of anticancer agents that have anti-
cancer effects in vitro and in vivo against cancers of lung, ova-
ries, breast, and leukemia . Recently, we have extended these
findings showing that Docetaxel induces caspase-dependent
apoptosis of some but not all human melanoma cell lines .
Resistance of cancer cells to taxanes has been attributed to
various mechanisms including over-expression of (multi-drug
resistance phenotype) P-glycoprotein that induces efflux of
the drug [5,6]. Other studies have reported that taxanes may
inappropriately induce activation of pro-survival signaling
pathways such as Ras–Raf–MEK–ERK pathway leading to
cancer cell resistance [7–9]. Studies have also shown that alter-
ation in the composition and mutations of b-tubulin isotypes,
can lead to resistance to taxanes [10,11]. Expression of mutant
tubulin or differential expression of certain tubulin isotypes has
been shown to correlate with the resistance profile of taxane-
resistant cells [10–12]. In some cases, the induced expression
of mutant tubulins  and b-tubulin isotypes classes III and
V [14,15] were shown to confer resistance to paclitaxel. Purified
mutant tubulins also have altered polymerisation characteris-
tics  and increased expression of classes I, III, and IVa iso-
types was reported in paclitaxel-resistant cells .
In the present study, we have explored the relation between
tubulin isotypes and sensitivity of melanoma cells to Docetaxel
and report that high level of class III b-tubulin can confer
resistance to Docetaxel-induced apoptosis. Moreover, a mech-
anism is suggested by the increased incorporation of class III
b-tubulin into the microtubular network in Docetaxel-resistant
2. Materials and methods
2.1. Cell lines
The panel of human melanoma cell lines used have been described
2.2. Antibodies and other reagents
Docetaxel (Taxotere), kindly provided by Aventis Pharma S.A
(France), was stored as a 100 mM solution in absolute ethanol at
?80 ?C and diluted immediately prior to use. The polyclonal anti-
Bax antibody was purchased from Upstate Biotechnology (Lake Pla-
cid, NY). The 107.3 mouse IgG1 antibody was purchased from
PharMingen (San Diego, CA). Monoclonal and polyclonal anti-a-
tubulin, classes I, III, and IV b-tubulin and b-actin were purchased
from Sigma–Aldrich (Castle Hill, NSW, Australia).
Quantitation of apoptotic cells by measurement of sub-G1 DNA
content using the PI method was carried out as described elsewhere
 under conditions established from previous work .
2.4. Measurement of tubulin polymerisation
Cytosolic and polymerised fractions of tubulin were separated by
differential centrifugation as previously described . Briefly cells
were lysed in microtubule-stabilizing buffer (20 mM Tris–HCl (pH
6.8), 0.14 M NaCl, 0.5% NP40, 1 mM MgCl2, 2 mM EGTA, and
10 ll/ml protease inhibitor cocktail (Sigma), with 4 lg/ml Docetaxel).
The polymerised fraction was obtained by collecting the supernatant
Abbreviation: MMP, mitochondrial membrane potential
*Corresponding author. Fax: +61 2 49236184.
E-mail address: Peter.Hersey@newcastle.edu.au (P. Hersey).
1These authors made an equal contribution towards the work.
0014-5793/$32.00 ? 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
FEBS Letters 582 (2008) 267–272
fraction after centrifuging the lysate at 10,000 · g for 20 min. The pel-
let (polymerised tubulin) was solubilised before electrophoresis in
SDS–PAGE sample buffer.
2.5. Indirect immunofluorescence and confocal microscopy
Melanoma cells seeded onto glass coverslips were fixed after the indi-
cated treatments before permeation with 0.1% Triton X-100. After
blocking with 3% bovine serum albumin, cells were immunostained
with primary antibodies before sequential detection with Alexa-488
anti-mouse IgG and or Alexa-594 anti-rabbit IgG (Invitrogen, Austra-
lia).In some experimentsnucleiwerevisualisedbyDAPI staining. After
mounting in SlowFade Gold reagent cells were examined using a Zeiss
Axioplan 2 epifluorescence microscope or Zeiss Axiovert 100 M fitted
with the LSM510 confocal system (Oberkochem, Germany).
2.6. Flow cytometry and mitochondrial membrane potential (DWm)
Flow cytometric analysis of permeabilised cells for Bax  and
mitochondrial membrane using JC-1 staining under established Doce-
taxel treatment conditions as previously described .
2.7. Western blot and protein expression analysis
Western blots were performed as described previously . Relative
expression was determined against control proteins (GAPDH or actin)
using densitometric analysis.
2.8. Small RNA interference (siRNA)
Transfections were performed for 48–72 h as previously described 
prior to each assay using either SiConTRol Non-targeting SiRNA
pool (D-001206-13-20) or the siGENOME SMARTpool for class III
b-tubulin (TUBB3) siRNA (Dharmacon, Lafayette, CO).
2.9. Cell viability assays
Cell viability assays were performed using the MTT method. After
siRNA treatment cells were seeded at 500 cells/well in 96 well plates
and allowed to adhere overnight before addition of Docetaxel. After
a further 72 h 30 ll of 5 mg/ml MTT (3-(4,5-dimethyl thiazolyl-2)-
2,5-diphenyl tetrazolium bromide; Sigma) was added to each well for
2 h. The supernatant was removed, the MTT formazan crystals dis-
solved in 100 ll of DMSO and the optical density read at 550 nm.
2.10. Statistical analysis
The statistical significance of intergroup differences was determined
using Student?s t-test. P values 60.05 and 60.001 are indicated by*
and**, respectively. Regression analyses were performed using the
3.1. Docetaxel-resistant melanoma cells have low levels of
Previous studies have shown that Docetaxel binds to the b-
tubulin subunit of the microtubules resulting in their polymer-
isation . We studied the Docetaxel-induced polymerisation
response of microtubules in the IgR3 and MM200 human mel-
anoma cell lines that have been shown previously to be differ-
entially sensitive to this agent . Lysates were prepared from
untreated and Docetaxel treated cells and the samples were
fractionated into soluble and polymerized tubulin fractions
as described in Section 2. Western blotting analysis showed
that under normal growth conditions, MM200 cells have a
lower level of polymerized tubulin compared to IgR3 cells
(Fig. 1A). Densitometric analysis showed that the percentage
of polymerized tubulin before and after treatment with Doce-
taxel was changed from 47% to 86% in IgR3 (P 6 0.05)
whereas a slight increase from 22% to 31% was seen in
Fig. 1. Docetaxel induces tubulin polymerisation in melanoma cells. (A) Soluble and polymerized fractions of tubulin were separated from cells
treated with or without Docetaxel at 20 nM for 3 h and the relative amounts were determined by Western blotting using antibodies against a-tubulin.
(B) Data collected from three individual experiments shown in (A) was analysed by densitometry (Columns, mean and bars, S.E.M.). (C) Cells were
also analysed by immunofluorescence microscopy for a-tubulin (green) and nuclear staining (DAPI; blue) under the treatment conditions described
for (A). bar = 20 lm.
N.M. Mhaidat et al. / FEBS Letters 582 (2008) 267–272
MM200 cells (Fig. 1B). These results were confirmed by immu-
nofluorescent staining showing in IgR3 cells that Docetaxel
treatment greatly intensified the microtubular network. In con-
trast, the microtubular network of MM200 cells was largely
unchanged with Docetaxel treatment (Fig. 1C).
3.2. Human melanoma cells have variable expression of classes
III and IV b-tubulin isotypes
The ability of taxanes to bind and polymerize tubulin was re-
ported to depend upon the expression of specific b-tubulin iso-
types [21,22]. The expression of various classes of b-tubulin
was examined in a panel of melanoma cell lines by immuno-
blotting. Fig. 2A shows that melanoma cells express classes
I, III, and IV b-tubulin. Expression of class I b-tubulin was
similar between different melanoma cells whereas classes III
and IV b-tubulin varied in expression levels (Fig. 2A and B).
Since we have shown previously that Docetaxel induces var-
iable degrees of apoptosis in melanoma cells  we examined
whether this variable expression of classes III and IV b-tubulin
tubulin levels correlated with sensitivity to Docetaxel. Fig. 2C
indicates that the expression of class III b-tubulin was inver-
sely correlated with the degree of Docetaxel-induced apopto-
sis. No significant correlations were seen between expression
of class IV b-tubulin and Docetaxel-induced apoptosis
(R2= 0.1699) or with an index considering the combined ef-
fects of class III plus class IV b-tubulin expression versus
apoptosis (data not shown).
Next, we examined the cellular distribution of class III b-
tubulin in both the sensitive IgR3 and the resistant MM200
cells before and after treatment with Docetaxel (Fig. 3). Before
treatment, the staining for class III b-tubulin in the IgR3 cells
revealed a largely cytoplasmic distribution whereas a propor-
tion of class III b-tubulin was clearly incorporated into the
microtubular network in the MM200 cells. Treatment with
Docetaxel caused little alteration in MM200 cells with much
of the class III b-tubulin retained in microtubules. In contrast,
Docetaxel caused significant disruption of IgR3 cells with class
III b-tubulin localised in membranous blebs and it did not ap-
pear to contribute to the microtubular network. The incorpo-
ration of class III b-tubulin into the microtubular network
therefore appears to phenotypically correlate to the mecha-
nism of melanoma resistance to Docetaxel.
3.3. Silencing of class III b-tubulin sensitized melanoma cells to
The results suggested that resistance of melanoma cells to
Docetaxel-induced apoptosis was due to high expression of
class III b-tubulin. We therefore examined whether modula-
tion of expression levels of class III b-tubulin altered Doce-
taxel-resistance in melanoma cells. As shown in Fig. 4A,
silencing of class III b-tubulin using siRNA inhibited expres-
sion by 79% in MM200 cells compared to the cells transfected
with a control siRNA. Expression levels of classes I and IV b-
tubulins were not affected emphasising the specificity of the
class III b-tubulin siRNA. Knockdown of class III b-tubulin
expression significantly enhanced microtubule polymerisation
(P 6 0.05) and this was accompanied by significant increases
in apoptosis induced by Docetaxel (Fig. 4B). This was partic-
ularly dramatic in the MM200 cells reverting these resistant
cells to a sensitive phenotype (P 6 0.001). The increased Doce-
taxel-induced apoptosis observed after class III b-tubulin
silencing was also accompanied by enhanced Bax activation
and increases in mitochondrial membrane potential (MMP)
changes (Fig. 4C; P 6 0.001). Furthermore, class III b-tubulin
siRNA increased the anti-proliferative effects of Docetaxel in
both MM200 and IgR3 cells, reducing the IC50 from ?30 to
10.5 nM and 9 to 2 nM respectively (Fig. 4D).
In order to determine if class III b-tubulin transfection could
increase the levels of resistance of IgR3 cells to Docetaxel, we
derived permanent transfectants of these cells over-expressing
class III b-tubulin (Suppl. Fig. 1A). Although these cells dis-
played expression of class III b-tubulin at levels similar to
Fig. 2. Expression of different b-tubulin isotypes in melanoma cells. (A) Total cellular protein from a panel of melanoma cells was subjected to
Western blots for classes I, III, and IV b-tubulins. (B) The relative expression of each class was determined by dividing the densitometric value against
a b-actin control. Columns, mean of three individual experiments; bars, S.E.. (C) Correlation between the relative expression of class III b-tubulin and
the levels of apoptosis induced by 20 nM Docetaxel after 48 h.
N.M. Mhaidat et al. / FEBS Letters 582 (2008) 267–272
MM200 cells (refer Fig. 2B), they were not more resistant to
Docetaxel in assays measuring apoptosis or cell viability (Sup-
pl. Fig. 1C and D). However permanent transfection of class
III b-tubulin did result in a modest increase in the expression
of a-tubulin (Suppl. Fig. 1B) that may account for this discrep-
ancy (see Section 4).
Fig. 3. Comparative distribution of a-tubulin with class III b-tubulin in IgR3 and MM200 melanoma cells before and after treatment with 20 nM
Docetaxel for 3 h. Results were recorded by dual colour confocal microscopy using monoclonal a-tubulin and class III b-tubulin polyclonal
antibodies, bar = 20 lm.
Fig. 4. Inhibition of class III b-tubulin expression sensitised melanoma cells to Docetaxel-induced apoptosis. (A) MM200 cells were transfected with
control or class III b-tubulin-specific siRNA (TUBB3) and whole cell lysates subjected to Western blot analysis for classes I, III, IV b-tubulins and a
control protein, b-actin. Data shown are representative of three individual experiments. (B) Measurements of apoptosis and tubulin polymerisation
in siRNA transfected IgR3 and MM200 cells were performed with or without 20 nM Docetaxel treatment after 48 and 3 h, respectively. (C)
Measurements of Bax activation and DWm by JC-1 staining in siRNA transfected IgR3 and MM200 cells were performed after 16–24 h with or
without 20 nM Docetaxol treatment. Data in B and C represent the means ± S.E. of three individual experiments. (D) IgR3 and MM200 cells were
treated with control or TUBB3 siRNA were subjected to the indicated dose titration of Docetaxel. After 72 h cell viability was measured using the
MTT assay. Data were averaged from triplicate determinations and normalised to the control condition, bars, S.E.M.
N.M. Mhaidat et al. / FEBS Letters 582 (2008) 267–272
In the present study, we have explored for the first time the
relationship between microtubular polymerisation, the expres-
sion of tubulin isotypes and the resistance of human melanoma
cell lines to Docetaxel. We have chosen to use a relatively large
panel of cell lines that have different intrinsic properties rather
than deriving resistant tumour sublines by selection with
increasingly higher doses of drugs. The latter method is often
used to mimic events that lead to acquired drug resistance
but we believe our approach, which has been far more compre-
hensive than many of the cited studies, may be advantageous
in minimising the likelihood of in vitro artefacts.
The results showed that there was generally a low rate of
tubulin polymerisation in resistant melanoma cells and that
sensitive cells responded by increasing the microtubular mass
whereas resistant cells did not. This result appeared entirely
consistent with the known mode of action of taxanes. Exami-
nation of b-tubulin isotype expression revealed there was very
little variation in class I tubulin expression. Rather the expres-
sion of class III b-tubulin, which varied widely between differ-
ent melanoma cell lines, appeared to be a major determinant of
the degree of tubulin polymerisation and to the resistance to
Docetaxel. This concept was confirmed using an siRNA med-
iated strategy where knockdown of class III b-tubulin en-
hanced Docetaxel-induced tubulin polymerisation, activation
of Bax and downstream apoptotic events that manifested in re-
duced cell proliferation.
In contrast to the results obtained using siRNA against class
III b-tubulin, we were unable to demonstrate that high level
expression of class III b-tubulin by transfection could promote
the resistance of IgR3 melanoma cells to Docetaxel. This
somewhat unexpected result has been previously reported.
For example, transfection of class III b-tubulin into prostate
cancer cells, which is upregulated in these cells by Paclitaxel
exposure, was unable to confer resistance to Paclitaxel and
other microtubule targeting agents . However, it was deter-
mined that stable transfection of class III b-tubulin actually
caused compensatory increases in the expression of a-tubulin
in conjunction with increases in both class II and class IV b-
tubulins. The authors of this work as well as Hari et al. 
have both flagged the difficulties encountered when using gene
transfection to assay the contribution of individual tubulin iso-
types. The mechanism of the compensatory phenomenon is not
well studied but appears to be acting through transcriptional
regulation  and this also appears to be occurring in the
IgR3 cells with a modest increase in a-tubulin expression noted
to occur. We conclude from our study that siRNA is a prefer-
able technique to demonstrate the functional effects on individ-
ual tubulin isotypes. This is probably because its effects
generally occur quite rapidly and its actions are effective
against the entire cell population under treatment.
While our study showed that class III b-tubulin appeared
important in unselected melanoma cell lines, studies in other
types of cancer cell lines have revealed that alterations in b-
tubulins occurs with resistance to microtubule-targeting drugs
although not always associated with a single isotype. For
example, the increased expression of classes III and IVa b-
tubulin has also been associated with the Paclitaxel-resistance
in non-small lung carcinoma cell lines  and in K562 eryth-
roleukemia cells . Docetaxel-resistant MCF-7 breast cancer
cells also exhibited increased expression of classes I, II, III and
IV b-tubulin isotypes whereas all isotypes examined except for
class IV were decreased in Docetaxel-resistant MB-MDA-231
breast cancer cells . Notwithstanding the differences ob-
served between various cancer cell lines, increased levels of
b-tubulins do appear to have significance for clinical outcomes
with taxanes. Samples of ovarian tumours from patients trea-
ted with Paclitaxel displayed increased levels of classes I, III
and IVa b-tubulins when compared to non-treated patients
. More recently, acquired expression of class III b-tubulin
was not seen in another study of ovarian cancer, however,
the pre-treatment level of this isotype did act as an indepen-
dent prognostic indicator of poor outcome . Similarly, in-
creased expression of classes I and III b-tubulin in breast
 and class III b-tubulin non-small cell lung cancer  also
appear to predict poor outcomes with Paclitaxel and Doce-
Questions still remain in regard to the mechanism(s) that
underlie the prognostic significance of b-tubulin isotypes.
One model proposed by Carbral and colleagues associates
unstable or dynamic microtubules with the resistance of cells
to microtubule targeting agents [29,30]. In accordance, when
class III b-tubulin is assembled into microtubules it has been
reported to result in more unstable microtubules  that are
less sensitive to Paclitaxel . In our study we observed that
Docetaxel-resistance in melanoma cells coincided with in-
creased class III b-tubulin incorporation into the microtubular
network. High levels of class III b-tubulin have also been re-
ported to reduce the assembly of microtubules  and this
is also consistent with our results measuring the percentages
of microtubular polymerisation. Together these data suggest
that the large monomeric pool of class III b-tubulin acts to
promote dynamic/unstable microtubules that in turn limits
the polymerised microtubular mass in response to Docetaxel.
Towards an understanding of how this process may be regu-
lated, we have recently reported that PKCe is associated with
pro-survival signaling through ERK in melanoma cells treated
with Docetaxel . Moreover PKCe was also shown to co-
immunoprecipitate with cytosolic class III b-tubulin suggesting
it may also be influencing the incorporation rates of class III b-
tubulin into microtubules.
To our knowledge no clinical data currently exists on the
expression of b-tubulin isotypes in melanoma in vivo. In light
of the work presented here there is now a need determine if
expression of class III b-tubulin can be correlated with tumour
responses in xenograft models and in melanoma patients trea-
ted with taxanes. It will also be important to better understand
the complex mechanisms governing the cellular regulation of
the tubulin repertoire that is clearly very important in deter-
mining how cells respond to taxanes.
Acknowledgements: This work was supported by the NSW State Can-
cer Council and National Health and Medical Research Council of
Australia. X.D. Zhang is a Cancer Institute NSW Fellow. The authors
would also like to thank Mr. Tiongsun Chia for his invaluable techni-
Appendix A. Supplementary material
Supplementary data associated with this article can be
N.M. Mhaidat et al. / FEBS Letters 582 (2008) 267–272
 Karin, M. (1995) The regulation of AP-1 activity by mitogen-
activated protein kinases. J. Biol. Chem. 270, 16483–16486.
 Bhalla, K.N. (2003) Microtubule-targeted anticancer agents and
apoptosis. Oncogene 22, 9075–9085.
 Rowinsky, E.K. and Donehower, R.C. (1991) The clinical
pharmacology and use of antimicrotubule agents in cancer
chemotherapeutics. Pharmacol. Ther. 52, 35–84.
 Mhaidat, N.M., Wang, Y., Kiejda, K.A., Zhang, X.D. and
Hersey, P. (2007) Docetaxel-induced apoptosis in melanoma cells
is dependent on activation of caspase-2. Mol. Cancer Ther. 6,
 Childs, S., Yeh, R.L., Hui, D. and Ling, V. (1998) Taxol
resistance mediated by transfection of the liver-specific sister gene
of P-glycoprotein. Cancer Res. 58, 4160–4167.
 Lecureur, V., Sun, D., Hargrove, P., Schuetz, E.G., Kim, R.B.,
Lan, L.B. and Schuetz, J.D. (2000) Cloning and expression of
murine sister of P-glycoprotein reveals a more discriminating
transporter than MDR1/P-glycoprotein. Mol. Pharmacol. 57, 24–
 Subbaramaiah, K., Hart, J., Norton, L. and Dannenberg, A.
(2000) Microtubule-interfering agents stimulate the transcription
of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND
p38 mitogen-activated protein kinase pathways. J. Biol. Chem.
 McDaid, H., Lopez-Barcons, L., Grossman, A. and Lia, M.
(2005) Enhancement of the therapeutic efficacy of taxol by the
mitogen-activated protein kinase kinase inhibitor CI1040 in nude
mice bearing human heterotransplants. Cancer Res. 65, 2854–
 Mhaidat, N.M., Zhang, X.D., Jiang, C.C. and Hersey, P. (2007)
Docetaxel-induced apoptosis of human melanoma is mediated by
activation of JNK and inhibited by the MAP Kinase ERK1/2
pathway. Clin. Cancer Res. 13, 1308–1314.
 Kavallaris, M., Kuo, D.Y., Burkhart, C.A., Regl, D.L.,
Norris, M.D., Haber, M. and Horwitz, S.B. (1997) Taxol-
resistant epithelial ovarian tumors are associated with altered
expression of specific beta-tubulin isotypes. J. Clin. Invest. 100,
 Ranganathan, S., Benetatos, C.A., Colarusso, P.J., Dexter, D.W.
and Hudes, G.R. (1998) Altered beta-tubulin isotype expression in
paclitaxel-resistant human prostate carcinoma cells. Br. J. Cancer
 Martello, L.A., Verdier-Pinard, P., Shen, H.J., He, L., Torres, K.,
Orr, G.A. and Horwitz, S.B. (2003) Elevated levels of microtubule
destabilizing factors in a taxol-resistant/dependent A549 cell line
with an alpha-tubulin mutation. Cancer Res. 63, 1207–1213.
 Gonzalez-Garay, M.L., Chang, L., Blade, K., Menick, D.R. and
Cabral, F. (1999) A beta-tubulin leucine cluster involved in
microtubule assembly and paclitaxel resistance. J. Biol. Chem.
 Bhattacharya, R. and Cabral, F. (2004) A ubiquitous beta-tubulin
disrupts microtubules assembly and inhibits cell proliferation.
Mol. Biol. Cell 15, 3123–3131.
 Hari, M., Yang, H.Y., Zeng, C., Canizales, M. and Cabral, F.
(2003) Expression of class III beta-tubulin reduces microtubule
assembly and confers resistance to paclitaxel. Cell Motil. Cyto-
skeleton 56, 45–56.
 Giannakakou, P., Sackett, D.L., Kang, Y.K., Zhan, Z., Buters,
J.T., Fojo, T. and Poruchynsky, M.S. (1997) Paclitaxel-resistant
human ovarian cancer cells have mutant beta-tubulins that exhibit
impaired paclitaxel-driven polymerization. J. Biol. Chem. 272,
 Zhang, X.D., Borrow, J.M., Zhang, X.Y., Nguyen, T. and
Hersey, P. (2003) Activation of ERK1/2 protects melanoma cells
from TRAIL-induced apoptosis by inhibiting Smac/DIABLO
release from mitochondria. Oncogene 22, 2869–2881.
 Zhang, X.D., Zhang, Y.D., Nguyen, D.T., Gray, C. and Hersey,
P. (2001) Regulation of TRAIL-induced apoptosis of melanoma
by release of Smac/DIABLO from mitochondria. Cancer Res. 61,
 Zhang, X., Franco, A., Myers, K., Gray, C., Nguyen, T. and
Hersey, P. (1999) Relation of TNF-related apoptosis-inducing
ligand (TRAIL) receptor and FLICE-inhibitory protein expres-
sion to TRAIL-induced apoptosis of melanoma. Cancer Res. 59,
 Jordan, M.A., Toso, R.J., Thrower, D. and Wilson, L. (1993)
Mechanism of mitotic block and inhibition of cell proliferation by
taxol at low concentrations. Proc. Natl. Acad. Sci. USA 90, 9552–
 Dumontet, C. (2000) Mechanisms of action and resistance to
tubulin-binding agents. Expert Opin. Invest. Drugs 9, 779–788.
 Burkhart, C.A., Kavallaris, M. and Band Horwitz, S. (2001) The
role of beta-tubulin isotypes in resistance to antimitotic drugs.
Biochim. Biophys. Acta 1471, 1–9.
 Ranganathan, S., McCauley, R.A., Dexter, D.W. and Hudes,
G.R. (2001) Modulation of endogenous b-tubulin isotype expres-
sion as a result of human bIIIcDNA transfection into prostate
cancer cells. Br. J. Cancer 85, 735–740.
 Jaffrezou, J., Dumontet, C., Derry, W., Duran, G., Chen, G.,
Tsuchiya, E., Wilson, L., Jordan, M. and Sikic, B. (1995) Novel
mechanism of resistance to paclitaxel (taxol) in human K562
leukemia cells by combined selection with PSC 833. Oncol. Res. 7,
 Shalli, K., Brown, I., Heys, S. and Schofield, A. (2005) Alterations
of b-tubulin isotypes in breast cancer cells resistant to docetaxel.
FASEB J. 19, 1299–1301.
 Ferrandina, G., Zannoni, G., Martinelli, E., Paglia, A., Gallotta,
V., Mozzetti, S., Scambia, G. and Ferlini, C. (2006) Class III beta-
tubulin overexpression is a marker of poor clinical outcome in
advanced ovarian cancer patients. Clin. Cancer Res. 12, 2774–
 Hasegawa, S., Miyoshi, Y., Egawa, C., Ishitobi, M., Taguchi, T.,
Tamaki, Y., Monden, M. and Noguchi, S. (2003) Prediction of
response to docetaxel by quantitative analysis of class I and III
beta-tubulin isotype mRNA expression in human breast cancers.
Clin. Cancer Res. 9, 2992–2997.
 Seve, P., Mackey, J., Isaac, S., Tredan, O., Souquet, P.J., Perol,
M., Lai, R., Voloch, A. and Dumontet, C. (2005) Class III beta-
tubulin expression in tumor cells predicts response and outcome
in patients with non-small cell lung cancer receiving paclitaxel.
Mol. Cancer Ther. 4, 2001–2007.
 Orr, G.A., Verdier-Pinard, P., McDaid, H. and Horwitz, S.B.
(2003) Mechanisms of taxol resistance related to microtubules.
Oncogene 22, 7280–7295.
 Panda, D., Miller, H.P., Banerjee, A., Luduena, R.F. and Wilson,
L. (1994) Microtubule dynamics in vitro are regulated by the
tubulin isotype composition. Proc. Natl. Acad. Sci. USA 91,
 Derry, W.B., Wilson, L., Khan, I.A., Luduena, R.F. and Jordan,
M.A. (1997) Taxol differentially modulates the dynamics of
microtubules assembled from unfractionated and purified beta-
tubulin isotypes. Biochemistry 36, 3554–3562.
 Mhaidat, N.M., Thorne, R.F., Zhang, X. and Hersey, P. (2007)
Regulation of docetaxel-induced apoptosis of human melanoma
cells by different isoforms of protein kinase C. Mol. Cancer Res. 5,
N.M. Mhaidat et al. / FEBS Letters 582 (2008) 267–272